Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Promising new developments in cancer chemotherapy.

K Ferrante1, B Winograd, R Canetta

  • 1Bristol-Myers Squibb Pharmaceutical Research Institute, Richard L. Gelb Center for Pharmaceutical Research and Development, Wallingford, CT 06492-7660, USA. ferrantk@bms.com

Cancer Chemotherapy and Pharmacology
|June 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives.

Neurology·2005
Same author

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2001
Same author

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

[New frontieres of treatment in oncology].

Tumori·2001
Same author

New developments in chemotherapy of advanced breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2000
Same author

Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.

Anti-cancer drugs·1999
Same journal

Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.

Cancer chemotherapy and pharmacology·2026
Same journal

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

Cancer chemotherapy and pharmacology·2026
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
See all related articles

New cancer therapies are emerging, including microtubule-targeting agents like paclitaxel, oral platinum compounds such as satraplatin, and novel inhibitors of enzymes like topoisomerase and matrix metalloproteinases (MMPs). These advancements offer improved treatment options for various solid tumors and drug-resistant cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Traditional chemotherapeutics have shown survival benefits, driving interest in newer cytotoxic and orally active agents with better therapeutic indices.
  • Advances in understanding human tumorigenesis pathways have led to mechanism-based targeted therapies.
  • Microtubules, targeted by taxanes like paclitaxel, are crucial for inhibiting mitotic progression and inducing apoptosis.

Purpose of the Study:

  • To review novel anticancer agents and therapeutic strategies under investigation.
  • To highlight compounds targeting microtubules, platinum-based therapies, and enzyme inhibitors.
  • To discuss emerging approaches including vaccination strategies and targeting oncogenes/tumor suppressor genes.

Main Methods:

  • Review of preclinical and clinical data for novel anticancer agents.

Related Experiment Videos

  • Focus on compounds with improved efficacy, oral bioavailability, and targeted mechanisms.
  • Exploration of therapeutic strategies including vaccination and gene-targeted therapies.

    • Main Results:

    • Paclitaxel and its analogues demonstrate efficacy in various solid tumors by stabilizing microtubules.
    • Oral platinum compounds (e.g., satraplatin) and chemopotentiators (e.g., DPPE) show promise, including in cisplatin-resistant lines.
    • Dual topoisomerase inhibitors (TAS-103), MMP inhibitors, and farnesyltransferase inhibitors targeting Ras pathways exhibit significant preclinical antitumor activity.

    Conclusions:

    • Novel therapeutic approaches targeting microtubules, platinum compounds, specific enzymes, and oncogenic pathways offer significant potential for future cancer chemotherapy.
    • Vaccination strategies and MMP inhibitors are being investigated for specific cancer settings and tumor progression.
    • Ongoing research by Bristol-Myers Squibb Pharmaceutical Research Institute is yielding promising candidates for effective cancer treatment.